Development of a mono‐specific anti‐VEGF bivalent nanobody with extended plasma half‐life for treatment of pathologic neovascularization

Vascular endothelial growth factor (VEGF) plays a crucial role in angiogenesis within solid cancers. Thus, targeting VEGF might be part of a feasible therapy for treating pathological neovascularization, and nanobodies ? derived from heavy chain‐only antibodies occurring within Camelidae ? are a novel class of nanometer‐sized antibodies possessing unique properties that could be developed into a promising therapeutic. However, nanobodies have a very short half‐life in vivo due to their small size. Development of a bivalent nanobody is one way to remediate the half‐life problem of nanobodies. Two identical anti‐VEGF nanobodies were connected using the hinge region of llama IgG2c. The recombinant plasmid (pHEN6c‐bivalent nanobody) was transformed into E.coli WK6 cells and expression of the bivalent nanobody construct was induced with 1mM Isopropyl β‐D‐1‐thiogalactopyranoside (IPTG). Recombinant bivalent nanobody was purified using nickel affinity chromatography and its activity on human endothelial cells was assessed using 3‐(4,5‐Dimethylthiazol‐2‐yr)‐2,5‐diphenyltetrazolium bromide (MTT), tube formation, and cell migration assays. The pharmacokinetic study was performed after intravenous (i.v.) injection of recombinant bivalent nanobody into six‐week‐old C57BL/6 mice. Recombinant bivalent nanobody performed significantly better than monovalent nanobody in inhibiting proliferation, tube formation, and migration of human endothelial cells. Pharmacokinetic results showed a 1.8‐fold longer half‐life of bivalent nanobody in comparison with the monovalent nanobody. These results underscore the potential of recombinant anti‐VEGF bivalent nanobody as a promising tool for development of a novel therapeutic with an extended plasma half‐life for VEGF‐related diseases.     

Design, synthesis, and molecular modeling of a novel amide-linked cyclic GnRH analogue cyclo(4-9)[Lys4,D-Trp6,Glu9]GnRH: stimulation of gonadotropin gene expression

This report describes the rational design, synthesis, and pharmacological properties of an amide-linked cyclic analogue of gonadotropin-releasing hormone (GnRH) namely Cyclo(4-9)[Lys(4),d-Trp(6),Glu(9)]GnRH. The conformationally restricted analogue is characterized by reduced flexibility of the peptide strand due to the introduction of a beta-turn mimetic through 4,9 residue amide cyclization. The cyclic analogue was found to stimulate gonadotropin gene expression in the goldfish pituitary with similar potency compared to two native forms of GnRH. Simulation studies based on ROE connectivities in linear GnRH and potency of cyclic analogue supports the His(2), Trp(3), Tyr(5) clustering considered important for triggering receptor activation.     

Autoimmune hemolytic anemia in children. A review of 80 cases

The records of 80 children with autoimmune hemolytic anemia (AHA) followed up in the same department between 1962 and 1971 were reviewed. The peak incidence was in the first 4 years of life. Predominance among males was noted. Two familial cases were observed. Two main clinical patterns were distinguished: an acute transient type and a prolonged chronic type. A statistically significant correlation was found between the presenting clinical, hematologic and immunologic features and the ultimate evolution of the disease into either clinical pattern. High titer cold agglutinins were very rarely observed. In no patient was an underlying malignant disease found. Although the onset was sometimes dramatic, all the patients with acute transient type recovered rapidly. The over-all mortality was 11.2 per cent. Cases were fatal exclusively among patients suffering from prolonged chronic type AHA associated with either thrombocytopenia or other disorders. Corticosteroid therapy was of constant effectiveness in transient cases but its results were variable in chronic cases. Sixteen patients with prolonged chronic type AHA underwent splenectomy. Response was favorable in patients with significant splenic sequestration of ⁵¹Cr-labeled red cells.